Search results

Publication date Communities Collections Article title Author(s) Journal/Conference
15 Apr 2024 Others Experimental Drug Development Centre Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines Subramanyam Vankadara, Zhiyuan Ke, Sifang Wang, Sin Yun Foo, Jayantha Gunaratne, May Ann Lee, Xiaoying Koh, C. S. Brian Chia Chemical Biology & Drug Design
28 May 2019 BMRC Bioinformatics Institute Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown Cancers
5 Aug 2015 BMRC p53 Laboratory A Search for Synergy in the Binding Kinetics of Trastuzumab and Pertuzumab Whole and F(ab) to Her2 Wai-Heng Lua, Samuel Ken-En Gan, David Philip Lane, Chandra Shekhar Verma NPJ Breast Cancer